| アブストラクト | The care and treatment of cancer patients has significantly changed in the last decade with a remarkable shift towards novel targeted therapies. These promising new drugs may represent effective and potentially life-saving therapeutic options in cancer patients, but are also emerging in the cardiotoxicity scenario for their arrhythmogenic potential due to their QT-prolonging activity. In this article we review the mechanisms underlying drug-induced QT interval prolongation and the classes of anticancer-targeted therapies most frequently responsible for this adverse event, with a particular focus on tyrosine kinase-targeting molecules. Since up to 49 % of serious adverse drug reactions (ADRs) and 58 % of potentially fatal ADRs may not appear on initial drug safety labels, we also review and discuss data from the post-marketing VigiBase((R)) safety reporting system, the World Health Organization's global database of ADRs. Finally, we discuss arrhythmic risk stratification and prevention strategies in the complex multiple-risk setting of cancer patients, paying particular attention to drug-drug interactions with common antimicrobial, psychotropic and antiemetic supportive care, and we also provide an electrocardiographic QT monitoring algorithm for patients who are candidates for targeted cancer therapies. |
|---|
| ジャーナル名 | Clinical drug investigation |
|---|
| Pubmed追加日 | 2016/9/18 |
|---|
| 投稿者 | Cuni, Rezarta; Parrini, Iris; Asteggiano, Riccardo; Conte, Maria Rosa |
|---|
| 組織名 | Department of Cardiology, Azienda Ospedaliera Ordine Mauriziano, Largo Filippo;Turati nr. 62, 10128, Turin, Italy. rezi.cuni@gmail.com.;Turati nr. 62, 10128, Turin, Italy.;Azienda Sanitaria Locale Torino 2 and Torino 3, Out of Hospital Cardiology;Service, Turin, Italy. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/27638052/ |
|---|
